Modeyso
MARKETERJAZZ PHARMACEUTICALS Modeyso is the first and only FDA-approved treatment for adult and pediatric patients aged 1 year and older with H3 K27M-mutant diffuse midline glioma (DMG) following progression after prior therapy. Dordaviprone is an orally administered, blood-brain barrier-penetrant small molecule imipridone that selectively targets dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP, activating … Continued